Diagnosing Tardive Dyskinesia

Author(s):

Jason Noel, PharmD, MPA, BCPP,Julie Dopheide, PharmD, BCPP, FASHP

Panelists discuss how clinicians rely on careful observation, standardized rating scales like the AIMS (Abnormal Involuntary Movement Scale), and comprehensive patient histories to diagnose tardive dyskinesia, while facing challenges in distinguishing it from other movement disorders due to symptom overlap and the need to rule out conditions like drug-induced parkinsonism, akathisia, and primary movement disorders.

EP: 1.Optimizing Tardive Dyskinesia Care: Strategies to Advance Treatment Approaches

Now Viewing

EP: 2.Diagnosing Tardive Dyskinesia

EP: 3.Impact of Tardive Dyskinesia on Quality of Life

EP: 4.Improving Outcomes Through Patient Education and Addressing Unmet Needs

EP: 5.Treatment Options for Tardive Dyskinesia

EP: 6.Long-Term Outcomes with VMAT2 Inhibitors

EP: 7.Safety Profile of VMAT2 Inhibitors and Impact on Treatment Selection

EP: 8.Management of Tardive Dyskinesia and Comorbidities

EP: 9.Shared Decision-Making in Tardive Dyskinesia

EP: 10.Strategies for Optimizing Therapy

EP: 11.Patient Journey and the Role of the Pharmacist

EP: 12.Patient Counseling and Management of Adverse Events

EP: 13.Dosing and Titration Considerations

EP: 14.Enhancing Adherence and Collaborative Care

EP: 15.Educational Resources to Support Patients

Video series above is prompted by the following:

What methods or tests are commonly used to diagnose TD in clinical practice, and what are the challenges associated with diagnosing TD, including differentiating it from other movement disorders?